Clinical Trial Update: Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase I study evaluating CBG002 CAR-T cell therapy for relapsed or refractory multiple myeloma; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CBG002 CAR-T Cell (CBG002 CAR-T cell)

Snippet

Sponsor: Carbiogene Therapeutics Co. Ltd. | Conditions: Multiple Myeloma | Phase 1 | Status: NOT_YET_RECRUITING